130 related articles for article (PubMed ID: 10910485)
21. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients.
Kroon HM; Moncrieff M; Kam PC; Thompson JF
Ann Surg Oncol; 2009 May; 16(5):1184-92. PubMed ID: 19224289
[TBL] [Abstract][Full Text] [Related]
22. Isolated limb perfusion for melanoma.
Kroon BB; Noorda EM; Vrouenraets BC; Nieweg OE
J Surg Oncol; 2002 Apr; 79(4):252-5. PubMed ID: 11920783
[No Abstract] [Full Text] [Related]
23. Hyperthermic isolated limb perfusion with tumor necrosis factor alone for melanoma.
Posner MC; Lienard D; Lejeune FJ; Rosenfelder D; Kirkwood J
Cancer J Sci Am; 1995; 1(4):274-80. PubMed ID: 9166488
[TBL] [Abstract][Full Text] [Related]
24. Functional morbidity of hyperthermic isolated regional perfusion of the extremities.
Olieman AF; Schraffordt Koops H; Geertzen JH; Kingma H; Hoekstra HJ; Oldhoff J
Ann Surg Oncol; 1994 Sep; 1(5):382-8. PubMed ID: 7850539
[TBL] [Abstract][Full Text] [Related]
25. A retrospective comparative study evaluating the results of mild hyperthermic versus controlled normothermic perfusion for recurrent melanoma of the extremities.
Klaase JM; Kroon BB; Eggermont AM; van Geel AN; Schraffordt Koops H; Oldhoff J; Liénard D; Lejeune FJ; Berkel R; Franklin HR
Eur J Cancer; 1995; 31A(1):58-63. PubMed ID: 7695980
[TBL] [Abstract][Full Text] [Related]
26. A clinical and pharmacokinetic study of isolated limb perfusion with heat and melphalan for melanoma.
Minor DR; Allen RE; Alberts D; Peng YM; Tardelli G; Hutchinson J
Cancer; 1985 Jun; 55(11):2638-44. PubMed ID: 3995475
[TBL] [Abstract][Full Text] [Related]
27. Circuit and protocol for hypoxic hyperthermic isolated limb perfusion to treat malignant melanoma.
Innet LM; Haripershad V; Van Den Berg J; Cooper L
Perfusion; 2001 Jul; 16(4):325-30. PubMed ID: 11486853
[TBL] [Abstract][Full Text] [Related]
28. Melphalan monitoring during hyperthermic perfusion of isolated limb for melanoma: pharmacokinetic study and 99mTc-albumin microcolloid technique.
Cattel L; Buffa E; De Simone M; Cesana P; Novello S; Dosio F; Ceruti M
Anticancer Res; 2001; 21(3C):2243-8. PubMed ID: 11501854
[TBL] [Abstract][Full Text] [Related]
29. Hyperthermic antiblastic perfusion with TNFalpha and melphalan in stage III limb melanoma patients: A phase I - II SITILO study.
Di Filippo F; Rossi CR; Garinei R; Anzà M; Cavaliere F; Botti C; Perri P; Di Filippo S; Di Angelo P; Principi F; Laurenzi L
J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):97-101. PubMed ID: 16767914
[TBL] [Abstract][Full Text] [Related]
30. Free-flap evolution after hyperthermic regional chemotherapy in the isolated limb for malignant melanoma.
Goldschmidt D; Van Geertruyden J; de Fontaine S
J Reconstr Microsurg; 1998 Aug; 14(6):397-9. PubMed ID: 9734842
[TBL] [Abstract][Full Text] [Related]
31. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US.
Beasley GM; Caudle A; Petersen RP; McMahon NS; Padussis J; Mosca PJ; Zager JS; Hochwald SN; Grobmyer SR; Delman KA; Andtbacka RH; Noyes RD; Kane JM; Seigler H; Pruitt SK; Ross MI; Tyler DS
J Am Coll Surg; 2009 May; 208(5):706-15; discussion 715-7. PubMed ID: 19476821
[TBL] [Abstract][Full Text] [Related]
32. Isolated limb perfusion with melphalan for melanoma.
Nieweg OE; Kroon BB
J Surg Oncol; 2014 Mar; 109(4):332-7. PubMed ID: 24421252
[TBL] [Abstract][Full Text] [Related]
33. Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. Swedish Melanoma Study Group.
Hafström L; Rudenstam CM; Blomquist E; Ingvar C; Jönsson PE; Lagerlöf B; Lindholm C; Ringborg U; Westman G; Ostrup L
J Clin Oncol; 1991 Dec; 9(12):2091-4. PubMed ID: 1960549
[TBL] [Abstract][Full Text] [Related]
34. [Hyperthermic-antiblastic perfusion in the treatment of tumor of the extremities].
Di Filippo F; Cavaliere F; Anzà M; Garinei R; Rossi CR; Deraco M; Perri P; Botti C; Cigna E
Suppl Tumori; 2002; 1(3):S35-7. PubMed ID: 12415785
[No Abstract] [Full Text] [Related]
35. Prophylactic hyperthermic limb perfusion in stage I melanoma.
Krige JE; King HS; Strover RM
Eur J Surg Oncol; 1988 Aug; 14(4):321-6. PubMed ID: 3044834
[TBL] [Abstract][Full Text] [Related]
36. Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs.
Klop WM; Vrouenraets BC; van Geel BN; Eggermont AM; Klaase JM; Nieweg OE; Kroon BB
J Am Coll Surg; 1996 Jun; 182(6):467-72. PubMed ID: 8646345
[TBL] [Abstract][Full Text] [Related]
37. Isolated limb perfusion for malignant melanoma.
Alexander HR; Fraker DL; Bartlett DL
Semin Surg Oncol; 1996; 12(6):416-28. PubMed ID: 8914206
[TBL] [Abstract][Full Text] [Related]
38. Isolated Limb Infusion and Isolated Limb Perfusion for Melanoma: Can the Outcomes of these Procedures be Compared?
Kroon HM; Thompson JF
Ann Surg Oncol; 2019 Jan; 26(1):8-9. PubMed ID: 30465218
[No Abstract] [Full Text] [Related]
39. Local and systemic toxicity in 'borderline true' hyperthermic isolated perfusion for lower limb melanoma.
Pace M; Galli A; Bellacci A
Melanoma Res; 1995 Oct; 5(5):371-6. PubMed ID: 8541729
[TBL] [Abstract][Full Text] [Related]
40. Current status of hyperthermic limb perfusion for in-transit melanoma.
Ross MI
Int J Hyperthermia; 2008 May; 24(3):205-17. PubMed ID: 18392999
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
